Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Britta Weigelt, Martee L Hensley, Dmitriy Zamarin
Programmed death-1 (PD-1) inhibitors are approved for therapy of gynecologic cancers with DNA mismatch repair deficiency (dMMR), although predictors of response remain elusive. We conducted a single-arm phase 2 study of nivolumab in 35 patients with dMMR uterine or ovarian cancers. Co-primary endpoints included objective response rate (ORR) and progression-free survival at 24 weeks (PFS24). Secondary endpoints included overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety...
April 23, 2024: Nature Medicine